Invega (Paliperidone) Dosing
For oral Invega (paliperidone extended-release tablets), start adults with schizophrenia at 6 mg once daily without titration; for schizoaffective disorder, also start at 6 mg once daily. 1
Oral Formulation Dosing
Schizophrenia - Adults
- Starting dose: 6 mg once daily (no titration required)
- Dose range: 3-12 mg once daily
- Dose adjustments: If increasing above 6 mg/day, wait at least 5 days between increments of 3 mg/day
- Maximum dose: 12 mg/day 1
While doses above 6 mg showed a trend toward greater efficacy, this must be balanced against dose-related adverse effects. Some patients respond adequately to 3 mg/day.
Schizophrenia - Adolescents (12-17 years)
- Starting dose: 3 mg once daily (no titration required)
- Dose adjustments: If needed, increase by 3 mg/day increments at intervals >5 days
- Important caveat: Higher doses (6 mg for <51 kg; 12 mg for ≥51 kg) showed no clear efficacy enhancement but increased adverse events 1
Schizoaffective Disorder - Adults
- Starting dose: 6 mg once daily (no titration required)
- Dose range: 3-12 mg once daily
- Dose adjustments: If needed, wait at least 4 days between increments of 3 mg/day
- Maximum dose: 12 mg/day 1
Administration
- Take with or without food
- Swallow whole - do not chew, divide, or crush
- Patients may see tablet shell in stool (this is normal) 1
Special Populations
Renal Impairment
Mild (CrCl 50-80 mL/min):
- Initial: 3 mg once daily
- Maximum: 6 mg once daily
Moderate to Severe (CrCl 10-50 mL/min):
- Initial: 1.5 mg once daily
- Maximum: 3 mg once daily
CrCl <10 mL/min: Not recommended 1
Hepatic Impairment
- Mild to moderate (Child-Pugh A and B): No adjustment needed
- Severe: Not studied 1
Elderly
- Use same dosing as younger adults if renal function is normal
- Adjust for age-related decline in creatinine clearance per renal impairment guidelines above 1
Long-Acting Injectable (LAI) Formulation
Initiation Regimen
The LAI formulation requires deltoid loading doses:
- Day 1: 234 mg (150 mg eq.) deltoid injection
- Day 8: 156 mg (100 mg eq.) deltoid injection
- No oral supplementation required 2, 3, 4
Needle selection for deltoid:
- <90 kg: 1-inch, 23-gauge needle
- ≥90 kg: 1.5-inch, 22-gauge needle 2
Maintenance Dosing (Monthly)
- Recommended dose: 117 mg (75 mg eq.) monthly
- Dose range: 39-234 mg (25-150 mg eq.)
- Injection sites: Deltoid (weight-adjusted needle) or gluteal (1.5-inch, 22-gauge)
- Flexibility: Day 8 dose ±2 days; monthly doses ±7 days 2, 3
Extended Formulations
PP3M (quarterly): Available for patients stabilized on PP1M for at least 4 months 5
PP6M (twice-yearly): Approved for patients stabilized on PP1M or PP3M, offering the longest dosing interval of any LAI antipsychotic 5, 6
Switching Strategies
From Oral Antipsychotics to LAI
- Initiate LAI the day after discontinuing oral antipsychotic
- Use standard initiation regimen (234 mg Day 1,156 mg Day 8) 2, 3
From Other LAIs to Paliperidone Palmitate
Avoid Concurrent Risperidone
Since paliperidone is risperidone's active metabolite, avoid combining to prevent additive exposure 1
Clinical Pearls
Efficacy onset: Significant symptom improvement occurs by Day 8 with the loading regimen, with continued improvement after the Day 8 injection 4
Relapse prevention: LAI formulations significantly delay time-to-relapse (NNT = 5) compared to placebo in stabilized patients 7, 8
Adherence advantage: Initial episode patients and those adhering to LAI show substantially lower relapse rates (11.11% vs 34.72% for non-initial episodes) 9
Missed doses: If maintenance injection window is exceeded, management depends on duration of delay and may require oral supplementation or restarting initiation regimen 10